ArticleInternational journal of nephrology2020
Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes.
Article in International journal of nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Prevalence of Sarcopenia and Its Impact on Cardiovascular Events and Mortality among Dialysis Patients: A Systematic Review and Meta-Analysis.Nutrients · 2022Pooled it
- Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: a systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2022Pooled it
- Prevalence and Risk Factors of Sarcopenia in People Receiving Dialysis: A Systematic Review and Meta-Analysis.Seminars in dialysisPooled it
- Bone as an endocrine regulator of lipid and energy metabolism.Reviews in endocrine & metabolic disorders · 2026Review
- Sarcopenia and associated factors in maintenance hemodialysis patients in Vietnam: A cross-sectional study.Medicine · 2026Article
- Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?International journal of molecular sciences · 2025Review
- Bone and muscle crosstalk in ageing and disease.Nature reviews. Endocrinology · 2025Review
- The Impact of Non-bone Metastatic Cancer on Musculoskeletal Health.Current osteoporosis reports · 2024Review
- Sclerostin: clinical insights in muscle-bone crosstalk.The Journal of international medical research · 2023Review
- Role of the Osteocyte in Musculoskeletal Disease.Current osteoporosis reports · 2023Review
- Crosstalk between bone and muscle in chronic kidney disease.Frontiers in endocrinology · 2023Review
- Relationships between Sclerostin, Leptin and Metabolic Parameters in Non-Dialysis Chronic Kidney Disease Males.Journal of personalized medicine · 2022Article
- Sclerostin in Excessive Drinkers: Relationships with Liver Function and Body Composition.Nutrients · 2022Article
- Bioelectrical Impedance Analysis for the Assessment of Body Composition in Sarcopenia and Type 2 Diabetes.Nutrients · 2022Review
- Can Overnutrition Lead to Wasting?-The Paradox of Diabetes Mellitus in End-Stage Renal Disease Treated with Maintenance Hemodialysis.Nutrients · 2022Observational
- Review
- Muscle-bone axis in children with chronic kidney disease: current knowledge and future perspectives.Pediatric nephrology (Berlin, Germany) · 2021Review
- Role of myokines and osteokines in cancer cachexia.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Circulating Levels of Sclerostin Predict Glycemic Improvement after Sleeve Gastrectomy.Nutrients · 2021Article
- Bone-Muscle Mutual Interactions.Current osteoporosis reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sclerostin (Scl) is an osteoblast-inhibiting glycoprotein that is secreted mainly by osteocytes and is regulated by hormonal changes and skeletal loading. Decreased physical function and high serum Scl concentrations have been reported in chronic renal failure patients but little is known to date about the differences between diabetic and non-diabetic patients on hemodialysis who are susceptible to both sarcopenia and bone fragility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.